What 908 Devices (MASS) said on its Q3 earnings call. 908 Devices (NASDAQ:MASS) reported record third-quarter revenue of $19 million, up 35% from a year earlier, and raised the low end of its 2026 revenue forecast as demand for its detection devices grew internationally. The company now expects full-year revenue of $68.5 million to $70 million, representing growth of 22% to 25% over 2025. Chief Financial Officer Joe Griffith said the revised range reflected the third-quarter performance and that there had been no significant shifts in order timing. 908 Devices shipped 308 devices in the quarter, excluding approximately 100 NIRLab devices, and ended the period with an installed base of about 4,400 devices, also excluding NIRLab. Chief Executive Officer and Co-Founder Kevin Knopp said the company was making progress toward adjusted EBITDA break-even while continuing to invest in growth. Financial results and outlook. Third-quarter revenue rose from $14 million a year earlier and included $1.2 million from NIRLab. Handheld product and service revenue increased 35% to $17.8 million, driven primarily by FTIR products and NIRLab law enforcement revenue. OEM and funded partnership revenue rose 42% to $1.1 million. Recurring revenue increased by $0.2 million to $5.1 million, or 27% of total revenue. Griffith said NIRLab software and subscriptions and higher FTIR service revenue contributed to the increase, partly offset by an expected decline in Mass Spec service revenue. Gross margin was unchanged at 53%, while adjusted gross margin fell 40 basis points to 58%. Griffith attributed the adjusted margin decline primarily to product mix, including lower-margin international sales. The net loss from continuing operations narrowed to $4.6 million from $14.9 million. Griffith said higher gross profit and lower non-cash charges related to contingent consideration helped reduce the loss, partly offset by higher selling, general and administrative expenses. The adjusted EBITDA loss was $1.7 million, compared with $1.8 million a year earlier. The company ended the quarter with $99.1 million in cash, cash equivalents and marketable securities and no outstanding debt. It continues to expect a full-year adjusted EBITDA loss in the mid-single-digit millions, approximately one-third lower than in 2025. Griffith said reaching the high end of the revenue forecast would require fourth-quarter growth of roughly 24% and execution on key customer opportunities, mainly involving VipIR and Mass Spec products. The outcome will depend on customer funding and the timing of order closures, he said. International orders and NIRLab expansion. International customers accounted for 40% of third-quarter revenue, twice their share in the prior-year period. The company shipped about two-thirds of a previously announced $6 million ProtectIR order from an Asia-Pacific corrections agency. It also secured two European government wins, including a defense framework agreement worth more than $2 million. Knopp said NIRLab adoption was broad-based, with more than half of the approximately 100 devices sold in the quarter going to customers new to the platform. Those included U.S. state and local agencies and international law enforcement customers. Daily scan volume averaged roughly one per minute, up 74% year over year, he said. Griffith said NIRLab could generate close to $3 million in revenue for 2026 if its fourth-quarter performance repeats the third quarter. He identified an opportunity for more than $5 million in 2027, while noting that it was still early. Asked about a decline in U.S. state and local revenue during the quarter, Griffith said the segment represented approximately 25% of quarterly revenue and more than 40% for the first nine months. He attributed the quarterly decrease mainly to the timing of MX908 placements after several large wins in the first half. Next-Generation MX908 and military opportunity. 908 Devices is targeting initial shipments of its next-generation MX908 to early-access customers by year-end. Knopp said the device is smaller and lighter than the current version and offers enhanced connected services. Management expects it to contribute to growth in 2027 through new customers and, over time, upgrades among the more than 3,000 existing MX908 devices. The company also delivered MX908 devices for testing to the U.S. Army office responsible for the AVCAD program. Knopp said the evaluation was a constructive sign that the government was considering a commercial off-the-shelf solution, though any potential orders would most likely come in 2027. The company's 2026 guidance excludes AVCAD revenue. Griffith said a commercial-product approach could carry margins in the mid-to-high 50% range, compared with potential OEM-level margins of 30% to 40%. Knopp said the company would provide its full 2027 outlook early next year. About 908 Devices (NASDAQ:MASS). 908 Devices Inc is a Boston-based analytical technology company that develops purpose-built mass spectrometers for use outside traditional laboratory environments. Its instruments are designed to provide rapid chemical and biological analysis in the field, helping users identify unknown substances and make time-sensitive decisions. The company's product portfolio includes the MX908 handheld mass spectrometer, which is used to detect and identify chemical threats, explosives, narcotics and other hazardous materials.

908 Devices reported second quarter 2026 revenue of $16.1 million, representing 23% year-over-year growth. The company, which provides detection devices, saw particularly strong momentum with US state and local government customers, who accounted for more than half of quarterly revenue. Chief Executive Officer Kevin Knopp attributed the performance to continued funding support at state and local levels. He noted this funding is driven by the need to modernise detection capabilities in response to evolving threats, including the ongoing fentanyl crisis, emerging synthetic drugs, and chemical hazards. The company discussed its second quarter results ending 30 June 2026 during an earnings call on 11 August 2026.

908 Devices reported 23% revenue growth in Q2 2026, driven by strong demand from US state and local customers purchasing fentanyl detection equipment. The company shipped more than 35 VipIR units this quarter and raised its full-year revenue guidance to $68 million–$70 million. The firm acquired NIRLAB for $13.5 million, introducing an AI-powered subscription model that is expected to contribute approximately $1 million per quarter in the second half of 2026. Adjusted EBITDA loss narrowed by 50% year-over-year due to cost structure improvements. Management expects to ship more than 100 VipIR devices in 2026, with potential upside to 150 units. A $6 million ProtectIR order for an Asia Pacific corrections agency will be delivered across Q3 and Q4.